Grants for City or township governments - Health

This funding opportunity is designed to support research centers in developing innovative vaccines against hepatitis C virus, targeting a wide range of applicants including universities, nonprofits, and government entities.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter-term outcomes such as weight loss and diabetes.Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk, and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter-term outcomes such as weight loss and diabetes. Background Obesity: Obesity will soon surpass smoking tobacco as the number one cause of preventable death both in the United States and worldwide. Bariatric (metabolic) surgery is the most effective strategy to achieve significant initial and sustained weight loss among individuals who are morbidly obese. Bariatric surgery provides dramatic improvement in metabolic function, associated with a reduction in type 2 diabetes mellitus (T2DM) and cardiovascular (CV) risk. Bariatric surgery also appears to reduce the risk of certain obesity-related cancers, although which cancers are favorably impacted vary by study, and the mechanism(s) driving this risk reduction is mostly speculative. Bariatric surgery is performed in over 250,000 people in the U.S. annually, and the frequency is rising. Studies evaluating which bariatric surgery procedure(s) are most effective in cancer risk reduction could help bring to light new pathways to target for cancer prevention. Bariatric Surgery: Importantly, it is not yet clear from clinical and preclinical studies if the benefit from bariatric surgery arises from weight loss alone or if there is also a surgery-specific benefit. One mechanism for a possible surgery-specific effect is elevated bile acids (BA), both intestinal and circulating, after gastric bypass surgery such as Roux-en-Y gastric bypass (RYGB) that are proposed to be central to weight loss and other metabolic benefits. The interaction between BA and intestinal microbes is also an area of intense interest. Studies have identified important changes after bariatric surgery in the composition and function of the gut microbiome, which may mediate bariatric surgery effects. Fecal microbiota transplantation (FMT) from humans or mice that had undergone bariatric surgery to germ-free recipient mice showed decreased weight gain and decreased adiposity are both transmissible traits. In addition, FMT induced important host metabolic changes including decreased energy harvest from the diet, increased resting energy expenditure, and increased lipid utilization. The data suggest a causal link between gut microbiota and the metabolic and weight loss effects of bariatric surgery. If validated, the findings will provide insight into the mechanisms driving the benefit of bariatric surgery on cancer risk and would be useful to further scientific understanding and patient care. Animal Models: Several diets or genetically induced animal models of obesity have consistently demonstrated the benefits of weight loss on cancer risk, and these obesity-induced tumor models may be adaptable to bariatric surgery studies, such as the Kras model of pancreatic cancer. Animal models have been developed to study the effects of bariatric surgery. Rodent animal models are most often used due to feasibility (low cost, ease of housing) and have been used extensively to study the mechanism(s) of bariatric surgery responsible for the reduction or elimination of T2DM and CV risk. However, very little has been reported on bariatric surgery and cancer risk despite the fact that both rat and murine models of mammary and other cancers develop in 6 months or less, making it feasible to assess mechanistic changes that influence cancer risk. Bariatric Surgery and Cancer Risk: Obese patients undergo bariatric surgery for a variety of reasons, including weight loss and improvement in metabolic dysfunction. Physician advice regarding the potential benefit of bariatric surgery and cancer risk reduction can currently only be given in generalities based on large-scale studies and not targeted to the individual. Many but not all bariatric surgery investigations document an overall cancer risk reduction among women but not men. Some but not all bariatric surgery studies have found that both women and men undergoing bariatric surgery have an increased risk of colorectal cancer (CRC). Older studies which assessed bariatric surgery and cancer risk may not be useful to guide targeted advice to patients, as one of the most common procedures performed in the past, gastric banding, is only performed in 1% of bariatric surgery procedures today. The two most common bariatric surgery procedures currently performed are sleeve gastrectomy and RYGB. As such, planned animal and/or human studies should focus on the mechanistic effects of the two procedures that are currently in common use. Human biospecimens and/or data may be available from cohorts to enhance the studies proposed including the Longitudinal Assessment of Bariatric Surgery (LABS), Adolescent Bariatrics: Assessing Health Benefits & Risks (Teen-LABS), and NCI Cohort Consortium Members. Applications that include collaborators from fields outside of cancer research will be given special programmatic consideration. Responsive applications may investigate animal models, human studies, or a combination of both. General Area of Research and Scope of Work for this FOA General Area of Research Examples of relevant areas of research include but are not limited to: Do alterations in cancer risk biomarkers occur before weight loss? If so, in what organ, tissue, or cell type do they originate? Is maximum weight loss or long-term weight loss more important for cancer risk reduction? If so, how do the two differ at a cellular and/or biochemical level? What mechanism(s) explain the evidence that bariatric surgery is more beneficial in cancer risk reduction in women than men? Does bariatric surgery increase or decrease the risk of CRC, and if so, what are the mechanism(s)? Which cancers are decreased in incidence by bariatric surgery, and what are the mechanism(s) that explain the effect? Are any cancers increased in incidence by bariatric surgery? If so, through what mechanism(s)? Does the specific bariatric surgery procedure have an impact on cancer risk? If so, what are the mechanism(s) driving the difference in impact? Does racial or ethnic background influence the impact of bariatric surgery on cancer risk, and if so, what are the mechanism(s) involved? How does bariatric surgery affect the penetrance of high-risk genetic predisposition to cancer? Scope of Work and Additional Guidance It is anticipated that studies will evaluate bariatric surgery animal models where a significant proportion of the animals develop cancer. Similarly, human studies involving individuals who will or have undergone bariatric surgery are also encouraged, so long as within the cohort to be studied the number of enrolled subjects who develop cancer is adequate to for a statistically powered endpoint linking cancer (and not a biomarker of cancer) to a molecular mechanism as the driver of cancer. When appropriate and feasible, the investigators may want to evaluate mechanisms influenced by bariatric surgery in animal models of cancer and evaluate potential changes that might correlate with humans due to bariatric surgery. We define mechanism as a biologic endpoint based on analyzed samples from bariatric surgery animal models or from subjects who have or are planned to undergo bariatric surgery. This FOA does not support studies where an epidemiologic endpoint is the primary aim of the project. The mechanism(s) to be studied should evaluate samples collected from animals or humans who have undergone bariatric surgery who did or did not develop cancer. If both animals and humans are studied, the mechanisms chosen should be based on a cancer endpoint. Applications Not Responsive to This FOA The following types of activities remain outside the scope of this FOA, and applications proposing them are non-responsive to this FOA and will not be reviewed. This FOA is not intended for epidemiologic studies, where the primary endpoint is the assessment of cancer in a cohort of animals or humans, which has undergone bariatric surgery and mechanistic studies evaluating bodily fluid or tissue samples are nonexistent or of secondary endpoints. Application that focuses entirely on in vitro investigations. Epidemiologic investigations as the primary focus of the application. Animal or human studies that do not evaluate tissue and/or bodily fluid samples collected from participants who have undergone bariatric surgery, some of which developed cancer after surgery. Application, which includes a clinical trial that does not have a bariatric surgeon as a key investigator on the team. NOTE: Applicants to this FOA are strongly encouraged to contact NCI staff as soon as possible in the development of the application (preferably no later than 12 weeks prior to the application due date) to discuss the details of their proposed clinical trial, so that NCI staff can help the applicant understand whether the proposed clinical trial is within the goals and mission of the NCI and is appropriate for this FOA.

This funding opportunity provides financial support for research projects that aim to improve the adoption and sustainability of effective health interventions, particularly in underrepresented communities, by addressing barriers and promoting equitable health outcomes.

This program provides funding to establish community-based telehealth resources that connect rural veterans with healthcare providers, improving their access to essential medical services.

This program provides funding to local governments, nonprofits, and redevelopment authorities in Pennsylvania to revitalize downtown areas and enhance community development through various improvement projects.

This funding opportunity provides financial support to organizations that help families experiencing homelessness access quality child care and educational programs.

This grant provides funding to health organizations in Cameroon to strengthen their ability to prevent, detect, and respond to public health threats and improve overall health security.

This funding opportunity supports research institutions and organizations conducting experimental studies with human participants to explore new brain stimulation techniques for treating substance use disorders.

The Kiwanis Club of Los Altos Foundation annually offers grants to organizations operating within the greater Los Altos area. Focused on supporting initiatives that align with their mission of “Serving the Children of the World,” the foundation grants financial aid to projects and programs benefiting the community, particularly youth and seniors. Eligible applicants must be 501(c)(3) organizations, with past recipients including diverse beneficiaries such as Tech Trek, Mentor Tutor Connection, and the Living Classroom. Application acceptance period is from October 1 to January 31 each year.

This funding opportunity is designed to help schools collect and utilize data to improve the health and well-being of adolescents by tracking their behaviors and experiences over time.

Will County has allocated $225,000 in grant funding to support early child care providers within the county. This grant program aims to enhance the quality of child care services by funding improvements in educational materials, physical environments, technology, and developmental support services. The program's mission aligns with fostering a robust early childhood education ecosystem, recognizing the critical role these providers play in child development and community well-being. The grant targets DCFS Licensed Childcare Providers located in Will County. Priority is given to providers serving specific populations, including children ages birth to five in Will County R3 Zones, those receiving Child Care Assistance Program (CCAP) funds, children 0-5 years of age whose families speak English as a Second Language (ESL), children in the Early Intervention program, children with developmental or medical diagnoses, and children with active Individually Education Plans (IEP) in the public school system. The impact goal is to strengthen the capacity of these providers to offer high-quality care, particularly to vulnerable populations, ensuring equitable access to developmental and educational resources. The program prioritizes several key areas for funding. These include the acquisition of educational materials such as books, art supplies, and STEAM/STEM resources; improvements to the physical environment including safety, sanitation, furniture, and air/water filtration; technology upgrades for security systems, computer software for administrative tasks, and parent communication; and developmental supports like screening tools, consultant hiring, social-emotional program enhancements, and health screenings. The focus is on creating safe, stimulating, and technologically advanced environments that cater to the holistic developmental needs of young children. Expected outcomes include improved learning environments, enhanced safety and health standards, more efficient administrative processes, and increased access to specialized developmental support services for children. Measurable results will be seen through the implementation of new educational tools, upgraded facilities, advanced technology systems, and the provision of targeted developmental interventions. The ultimate goal is to contribute to the overall well-being and readiness for school of Will County's young children, thereby supporting the county's broader strategic priorities in early childhood development and community health.

This funding opportunity provides up to $40,000 for community groups and local agencies in the Oklahoma City Metro area to enhance public spaces through projects like tree planting and landscaping that promote public engagement and accessibility.

The Indiana Department of Health (IDOH) is offering a grant opportunity to provide intranasal naloxone kits to first responders in rural counties of Indiana. The grant, funded in part by the Substance Abuse Mental Health Services Administration (SAMHSA) under the First Responder Comprehensive Addiction and Recovery Act, aims to enhance the capacity of first responders to address opioid-related incidents. Eligible first responders include professional and volunteer firefighters, law enforcement officers, paramedics, emergency medical technicians, and other recognized volunteer organizations. Grant recipients are required to administer naloxone as needed, report usage via an online survey, and refrain from selling or distributing the naloxone doses. The grant period runs from October 2023 through September 2024, with a total funding amount of $287,500 available. Non financial aid, only Naloxone kits

This funding opportunity supports researchers and organizations in developing advanced tissue-engineered technologies that mimic cancer biology to improve cancer detection, treatment, and prevention.

This funding opportunity is designed to strengthen clinical and translational research capabilities in health organizations located in underserved states, enabling them to address local healthcare challenges through enhanced infrastructure, workforce development, and community engagement.

This funding opportunity provides financial support for organizations to develop and validate digital therapeutic technologies designed to treat substance use disorders, with the goal of achieving FDA authorization.

The Illinois Department of Commerce and Economic Opportunity (DCEO) is offering two grant programs: the Rebuild Downtowns & Main Streets (RDMS) Capital Grant Program and the Research in Illinois to Spur Economic Recovery (RISE) Implementation Grant Program. Both programs aim to accelerate Illinois' economic recovery and promote long-term, sustainable, and inclusive growth, aligning with a mission to revitalize communities and foster economic development. The total funding expected is $20 million for RDMS and $10 million for RISE Implementation, with individual grants ranging from $250,000 to $2 million. The RDMS program specifically targets communities that have experienced disinvestment, particularly those hardest-hit by the COVID-19 crisis. The goal is to facilitate investment to revitalize commercial corridors and downtown areas in Illinois through capital grants. Eligible applicants for both programs include economic development organizations (EDOs), local units of government (e.g., municipalities, counties, townships), and private businesses. Special purpose local units of government are not eligible. The priorities for RDMS include supporting capital projects that improve and repair roads, sidewalks, and lighting; develop public spaces to attract events; improve water and sewer infrastructure; and facilitate mixed-use development to add vitality to commercial corridors and downtowns. These priorities are aimed at tangible infrastructure and development projects that directly contribute to the revitalization of downtown areas. Expected outcomes for these programs include accelerated economic recovery and the promotion of long-term, sustainable, and inclusive growth throughout Illinois. Measurable results will likely involve the number and scale of capital projects completed, the revitalization of commercial corridors, increased economic activity in targeted areas, and improvements in public infrastructure. The grant duration is 2 years, with the period of performance expected to be late calendar year 2024 through the end of calendar year 2026. The DCEO's strategic priority is clearly to stimulate economic recovery and growth through targeted investments in key community infrastructure and development.

This grant provides funding for clinical trials investigating the safety and effectiveness of amyloid-beta antibody therapies in patients with mild cognitive impairment or dementia who also show signs of Lewy Body Dementia, with a focus on diverse and underrepresented populations.

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

The purpose of this Notice of Funding Opportunity (NOFO) is to stimulate translational efforts in developing and implementing accessibility devices or interventions that apply new technologies to address challenges faced by individuals living with visual impairment. Critical elements of applications include a clear set of milestones that support development and testing of the tool, device, or intervention proposed; multidisciplinary and collaborative teams that include individuals with lived experience; and a tractable dissemination plan. The overall goal of the program is to push the boundaries of innovation in technology development to address accessibility needs of individuals with visual impairment and create resources that will be made available to the community. This NOFO uses a milestone driven and phased mechanism of award. Initial technology development and feasibility activities (R61 phase) may transition to expanded research support (R33 phase) for validation, larger-scale feasibility, and effectiveness studies. All applications must address both R61 and R33 phases.